Inhibition of MRSA and of Clostridium difficile by durancin 61A: Synergy with bacteriocins and antibiotics

Future Microbiology

Volumn 12, Issue 3, 2017, Pages 205-212

  Hanchi, Hasna ^a,b   Hammami, Riadh ^a   Gingras, Hélène ^c   Kourda, Rim ^b   Bergeron, Michel G ^c   Ben Hamida, Jeannette ^b   Ouellette, Marc ^c   Fliss, Ismail ^a  

^a UNIVERSITÉ LAVAL   (Canada)

^b University Tunis El Manar   (Tunisia)

^c LAVAL UNIVERSITY   (Canada)

Author keywords

antibiotics; bacteriocins; clinical pathogens; drug resistance; synergy

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BACTERIOCIN; DURANCIN; DURANCIN 61A; MICROCIN J25; NISIN; PEDIOCIN; TETRACYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CONCENTRATION RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; IN VITRO STUDY; INHIBITORY CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; PRIORITY JOURNAL; CHEMISTRY; DRUG EFFECTS; ENTEROCOCCUS; GENETICS; ISOLATION AND PURIFICATION; METABOLISM; MICROBIAL SENSITIVITY TEST; PHYSIOLOGY;

ANTI-BACTERIAL AGENTS; BACTERIOCINS; CLOSTRIDIUM DIFFICILE; DRUG SYNERGISM; ENTEROCOCCUS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; NISIN; TETRACYCLINE; VANCOMYCIN;

EID: 85014652120     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb-2016-0113     Document Type: Article

References (33)

1. Nikaido H. Multidrug resistance in bacteria. Annu. Rev. Biochem. 78, 119-146 (2009).
2. Ager S, Gould K. Clinical update on linezolid in the treatment of Gram-positive bacterial infections. Infect. Drug Resist. 5, 87-102 (2012).
3. Den Hollander JG, Mouton JW, Verbrugh HA. Use of pharmacodynamic parameters to predict effcacy of combination therapy by using fractional inhibitory concentration kinetics. Antimicrob. Agents Chemother. 42(4), 744-748 (1998).
4. Luders T, Birkemo GA, Fimland G, Nissen-Meyer J, Nes IF. Strong synergy between a eukaryotic antimicrobial peptide and bacteriocins from lactic acid bacteria. Appl. Environ. Microb. 69 (3), 1797-1799 (2003).
5. Hammami R, Fernandez B, Lacroix C, Fliss I. Anti-infective properties of bacteriocins: an update. Cell Mol. Life Sci. 70(16), 2947-2967 (2013).
6. Cotter PD, Hill C, Ross R P. Bacteriocins: developing innate immunity for food. Nature Rev. Microbiol. 3(10), 777-788 (2005).
7. Arnison PG, Bibb MJ, Bierbaum G et al. Ribosomally synthesized and post-translationally modifed peptide natural products: overview and recommendations for a universal nomenclature. Nat. Prod. Rep. 30(1), 108-160 (2013).
8. Helander IM, Vonwright A, Mattilasandholm TM. Potential of lactic acid bacteria and novel antimicrobials against Gram-negative bacteria. Trends Food Sci. Technol. 8(5), 146-150 (1997).
9. Ganzle MG, Holtzel A, Walter J, Jung G, Hammes W P. Characterization of reutericyclin produced by Lactobacillus reuteri LTH2584. Appl. Environ. Microb. 66 (10), 4325-4333 (2000).
10. Morin N, Lanneluc I, Connil N, Cottenceau M, Pons AM, Sable S. Mechanism of bactericidal activity of microcin L in Escherichia coli and Salmonella enterica. Antimicrob. Agents Chemother. 55(3), 997-1007 (2011).
11. Lopez FE, Vincent PA, Zenoff AM, Salomon RA, Farias RN. Effcacy of microcin J25 in biomatrices and in a mouse model of Salmonella infection. J. Antimicrob. Chemother. 59(4), 676-680 (2007).
12. Svetoch EA, Levchuk VP, Pokhilenko VD et al. Inactivating methicillin-resistant Staphylococcus aureus and other pathogens by use of bacteriocins OR-7 and E 50-52. J. Clin. Microbiol. 46(11), 3863-3865 (2008).
13. Mota-Meira M, Morency H, Lavoie MC. In vivo activity of mutacin B-Ny266. J. Antimicrob. Chemother. 56(5), 869-871 (2005).
14. Kruszewska D, Sahl HG, Bierbaum G, Pag U, Hynes SO, Ljungh A. Mersacidin eradicates methicillin-resistant Staphylococcus aureus (MRSA) in a mouse rhinitis model. J. Antimicrob. Chemother. 54(3), 648-653 (2004).
15. Ingham A, Ford M, Moore RJ, Tizard M. The bacteriocin piscicolin 126 retains antilisterial activity in vivo. J. Antimicrob. Chemother. 51(6), 1365-1371 (2003).
16. Rea MC, Clayton E, O'connor PM et al. Antimicrobial activity of lacticin 3147 against clinical Clostridium diffcile strains. J. Med. Microbiol. 56(7), 940-946 (2007).
17. Draper LA, Cotter PD, Hill C, Ross RP. The two peptide lantibiotic lacticin 3147 acts synergistically with polymyxin to inhibit Gram negative bacteria. BMC Microbiol. 13(1), 212 (2013).
18. Brumftt W, Salton MR, Hamilton-Miller JM. Nisin, alone and combined with peptidoglycan-modulating antibiotics: activity against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci. J. Antimicrob. Chemother. 50(5), 731-734 (2002).
19. Naghmouchi K, Le Lay C, Baah J, Drider D. Antibiotic and antimicrobial peptide combinations: synergistic inhibition of Pseudomonas fuorescens and antibiotic-resistant variants. Res. Microbiol. 163(2), 101-108 (2012).
20. Hanchi H, Hammami R, Kourda R, Ben Hamida J, Fliss I. Bacteriocinogenic properties and probiotic potential of enterococci from Tunisian dairy products. Arch. Microbiol. 196(5), 331-344 (2014).
21. NCCLS: performance standards for antimicrobial susceptibility testing: 26th Ed. CLSI supplement. Document M100-S26 (2016).
22. Daba H, Lacroix C, Huang J, Simard RE, Lemieux L. Simple method of purifcation and sequencing of a bacteriocin produced by Pediococcus acidilactici U L5. J. Appl. Bacteriol. 77(6), 682-688 (1994).
23. Bouksaim M, Lacroix C, Bazin R, Simard RE. Production and utilization of polyclonal antibodies against nisin in an ELISA and for immuno-location of nisin in producing and sensitive bacterial strains. J. Appl. Microbiol. 87(4), 500-510 (1999).
24. Hanchi H, Hammami R, Kourda R, Ben Hamida J, Fliss I. Simultaneous production of formylated and non-formylated enterocins L50A and L50B, and 61A, a new glycosylated durancin, by Enterococcus durans 61A, a strain isolated from artisanal fermented milk in Tunisia. J. Agric. Food Chem. 64 (18), 3584-3590 (2016).
25. Sable S, Pons AM, Gendron-Gaillard S, Cottenceau G. Antibacterial activity evaluation of microcin J25 against diarrheagenic Escherichia coli. Appl. Environ. Microbiol. 66 (10), 4595-4597 (2000).
26. Cleusix V, Lacroix C, Vollenweider S, Duboux M, Le Blay G. Inhibitory activity spectrum of reuterin produced by Lactobacillus reuteri against intestinal bacteria. BMC Microbiol. 7, 101 (2007).
27. Bakar NS, Zin NM, Basri DF. Synergy of favone with vancomycin and oxacillin against vancomycin-intermediate Staphyloccus aureus. Pak. J. Pharm. Sci. 25(3), 633-638 (2012).
28. Dicks LMT, Ten Doeschate K. Enterococcus mundtii ST4SA and Lactobacillus plantarum 423 alleviated symptoms of Salmonella infection, as determined in wistar rats challenged with Salmonella enterica serovar Typhimurium. Curr. Microbiol. 61(3), 184-189 (2010).
29. De Kwaadsteniet M, Todorov SD, Knoetze H, Dicks LMT. Characterization of a 3944 Da bacteriocin, produced by Enterococcus mundtii ST15, with activity against Gram-positive and Gram-negative bacteria. Int. J. Food Microbiol. 105(3), 433-444 (2005).
30. Line JE, Svetoch EA, Eruslanov BV et al. Isolation and purifcation of enterocin E-760 with broad antimicrobial activity against Gram-positive and Gram-negative bacteria. Antimicrob. Agents Chemother. 52(3), 1094-1100 (2008).
31. El-Ziney MG, Debevere JM. The effect of Reuterin on Listeria monocytogenes and Escherichia coli O157:H7 in milk and cottage cheese. J. Food Prot. 61(10), 1275-1280 (1998).
32. Vignolo G, Palacios J, Farias ME et al. Combined effect of bacteriocins on the survival of various Listeria species in broth and meat system. Curr. Microbiol. 41(6), 410-416 (2000).
33. Beceiro A, Tomás M, Bou G. Antimicrobial resistance and virulence: a successful or deleterious association in the bacterial world? Clin. Microbiol. Rev. 26(2), 185-230 (2013).